November 18, 2020 -- Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.
It has been dubbed the "super plant" because the new, multistory 238,000-sq-mt facility will boast 256,000 L of total manufacturing capacity. Once completed, it will be the largest biopharmaceutical manufacturing facility in the world, according to the company.
Samsung Biologics Plant 4 groundbreaking ceremony. Image courtesy of Samsung Biologics.
With this plant, Samsung Biologics anticipates being responsible for a third of the total global bio-contract manufacturing organization capacity, offering a combined sum of 620,000 L from a single site. Plant 4 will feature a modular design, allowing for certain parts of the facility to begin manufacturing by the end of 2022. The plant is expected to be fully operational in 2023.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
